Chargement en cours...
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
PI3K-AKT-mTOR and Ras-Raf-MEK-ERK are the most commonly altered oncogenic pathways in solid malignancies. There has been a lot of enthusiasm to develop inhibitors to these pathways for cancer therapy. Unfortunately, the antitumor activities of single-agent therapies have generally been disappointing...
Enregistré dans:
| Publié dans: | Ther Adv Med Oncol |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE Publications
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4406912/ https://ncbi.nlm.nih.gov/pubmed/26673580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834015571111 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|